HGWM
BMRN icon

Harvest Group Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Harvest Group Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-24
Closed -$2K – 913
2019
Q1 		$2K Buy
+24
New +$2.22K ﹤0.01% 588

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Harvest Group Wealth Management's BMRN Position: Q2 2019 in Review

Harvest Group Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 24 shares — an estimated $2K sold.

Harvest Group Wealth Management first reported a position in BMRN in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

  • Harvest Group Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Harvest Group Wealth Management sold 24 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $2K.
  • Harvest Group Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Harvest Group Wealth Management's BioMarin Pharmaceuticals position peaked at $2K in Q1 2019.
  • 482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Harvest Group Wealth Management's 13F filing for Q2 2019, filed 31 Jul 2019.